6533b821fe1ef96bd127b05c

RESEARCH PRODUCT

Epigenetic IVD Tests for Personalized Precision Medicine in Cancer

Jesús Beltrán-garcíaJesús Beltrán-garcíaJesús Beltrán-garcíaRebeca Osca-verdegalRebeca Osca-verdegalSalvador Mena-molláSalvador Mena-molláJosé Luis García-jiménezJosé Luis García-giménezJosé Luis García-giménezJosé Luis García-giménez

subject

0301 basic medicineIn Vitro Diagnostic (IVD)lcsh:QH426-470precision medicineReviewBioinformatics03 medical and health sciences0302 clinical medicinemicroRNAGeneticsMedicineEpigeneticscfDNAGenetics (clinical)miRNAEpigenetic biomarkersDNA methylationbiologybusiness.industryCancerepigenetic biomarkerPrecision medicinemedicine.diseaselcsh:Genetics030104 developmental biologyHistone030220 oncology & carcinogenesisDNA methylationcirculating nucleosomesbiology.proteinMolecular MedicinebusinessGlioblastoma

description

Epigenetic alterations play a key role in the initiation and progression of cancer. Therefore, it is possible to use epigenetic marks as biomarkers for predictive and precision medicine in cancer. Precision medicine is poised to impact clinical practice, patients, and healthcare systems. The objective of this review is to provide an overview of the epigenetic testing landscape in cancer by examining commercially available epigenetic-based in vitro diagnostic tests for colon, breast, cervical, glioblastoma, lung cancers, and for cancers of unknown origin. We compile current commercial epigenetic tests based on epigenetic biomarkers (i.e., DNA methylation, miRNAs, and histones) that can actually be implemented into clinical practice.

10.3389/fgene.2019.00621https://www.frontiersin.org/article/10.3389/fgene.2019.00621/full